Your browser doesn't support javascript.
loading
Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta-analysis.
Mehta, Tej I; Weissman, Simcha; Fung, Brian M; Sotiriadis, John; Lindor, Keith D; Tabibian, James H.
Afiliação
  • Mehta TI; Department of Radiology, Johns Hopkins University Hospital, Baltimore, MD, USA.
  • Weissman S; Department of Medicine, Hackensack University-Palisades Medical Center, North Bergen, NJ, USA.
  • Fung BM; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.
  • Sotiriadis J; Division of Gastroenterology and Hepatology, Hackensack University-Palisades Medical Center, North Bergen, NJ, USA.
  • Lindor KD; College of Health Solutions, Arizona State University, Phoenix, AZ, USA.
  • Tabibian JH; Division of Gastroenterology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA, USA.
Liver Int ; 41(10): 2418-2426, 2021 10.
Article em En | MEDLINE | ID: mdl-34224208
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an idiopathic, cholestatic liver disease with a diverse range of clinical manifestations. Inter-regional data on PSC are variable, but its global geoepidemiology has not been well-studied. We aimed to examine the worldwide incidence, prevalence and features of PSC and PSC-inflammatory bowel disease (PSC-IBD). METHODS: A systematic search of multiple databases was conducted to identify all original, full-text studies until December 2020 with data regarding the incidence rate (IR) and/or prevalence of PSC. Outcomes were PSC IR, prevalence, features and IBD concurrence. Additionally, a meta-analysis of PSC IR was performed. The study was registered in PROSPERO (CRD42021224550). RESULTS: Of the 1003 studies identified, 17 studies spanning three continents were included. PSC IR was 0.60 per 100 000 person-years (PY) (95% confidence interval: 0.37-0.88 per 100 000 PY). In pooled subgroup analysis for studies conducted in Europe and North America, PSC IR was 0.62 and 0.53 per 100 000 PY, respectively. PSC prevalence ranged 0-31.7 per 100 000 persons, with notable inter-regional differences. Mean age at PSC diagnosis was bimodally distributed, with relative peaks at 15 and 35 years. Mean concurrence of IBD with PSC was 50%, with 76% having ulcerative colitis, 17% Crohn's disease and 8% indeterminate/unspecified IBD. CONCLUSION: While considerable heterogeneity exists in the geoepidemiology of PSC, overall, the classical dogmata of male predilection, bimodal distribution of mean age and high PSC-IBD concurrence appear to hold true. Despite a seemingly stable IR over time, further studies are needed to better understand the geoepidemiology of PSC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colangite Esclerosante / Doenças Inflamatórias Intestinais / Colite Ulcerativa / Doença de Crohn Tipo de estudo: Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans / Male Idioma: En Revista: Liver Int Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colangite Esclerosante / Doenças Inflamatórias Intestinais / Colite Ulcerativa / Doença de Crohn Tipo de estudo: Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans / Male Idioma: En Revista: Liver Int Ano de publicação: 2021 Tipo de documento: Article